Advocacy starts with information. Learn more about the evidence that shows PrEP works.
Pre-exposure prophylaxis, or PrEP, is a way to help HIV-negative people protect themselves from getting HIV. PrEP involves the use of antiretroviral drugs to reduce the risk of becoming infected with HIV. Daily oral PrEP is increasingly available since it was first approved by the US FDA in 2012. The Dapivirine Vaginal Ring and injectable cabotegravir (CAB-LA) are currently moving through the regulatory process. Other PrEP options are moving through the pipeline of research and development.
Get simple, straightforward information about what PrEP is and how it works.
Learn more about oral PrEP, the first ARV-based biomedical prevention method approved for HIV prevention.
PrEP research spans implementation research on delivering PrEP and clinical trials of new options. Learn more about the research and data behind the approvals, findings from national introduction and scale-up, and what products might be next.
Learn more about the Dapivirine Ring, an intravaginal silicone ring used for HIV prevention.
Efficacy data shows that the ring reduces HIV risk by 35 percent, with recent data from open label studies showing greater reduction in HIV risk – 50 percent or more with consistent use of the ring.
Learn more about CAB-LA, or long-acting injectable cabotegravir, an antiretroviral drug formulated to be administered once every two months as an injectable form of PrEP.
Data from two studies showed CAB-LA to be effective, safe, and well-tolerated in cisgender MSM, TGW, as well as cisgender women.
PrEPWatch Resource Database
Want something specific? Visit the PrEPWatch Resource Database where you can search using assorted parameters and keywords.